Results 1 to 10 of about 886 (145)

Circulating DNA fragmentomics and cancer screening

Cell Genomics, 2023
Summary: The high fragmentation of nuclear circulating DNA (cirDNA) relies on chromatin organization and protection or packaging within mononucleosomes, the smallest and the most stabilized structure in the bloodstream.
A R Thierry
exaly   +6 more sources

Cell-Free DNA Fragmentomics in Liquid Biopsy

Diagnostics, 2022
Cell-free DNA (cfDNA) in bodily fluids has rapidly transformed the development of noninvasive prenatal testing, cancer liquid biopsy, and transplantation monitoring. Plasma cfDNA consists of a mixture of molecules originating from various bodily tissues.
Spencer C Ding, Y M Dennis Lo, Y M Dennis Lo   +2 more
exaly   +5 more sources

Analysis of cfDNA fragmentomics metrics and commercial targeted sequencing panels [PDF]

Nature Communications
Fragmentomics based analysis of cell-free DNA (cfDNA) has recently emerged as a method to infer epigenetic and transcriptional data. Many of these reports analyze whole genome sequencing (WGS) which is not readily available clinically.
Kyle T. Helzer, Marina N. Sharifi, Jamie M. Sperger, Matthew R. Chrostek, Matthew L. Bootsma, Shannon R. Reese, Amy Taylor, Katie R. Kaufmann, Hannah Krause, Jennifer Schehr, Nan Sethakorn, David Kosoff, Christos E. Kyriakopoulos, Michael Bassetti, Grace Blitzer, John Floberg, Martin Sjöström, Andrew J. Armstrong, Himisha Beltran, Rana R. McKay, Felix Y. Feng, Ruth O’Regan, Kari B. Wisinski, Hamid Emamekhoo, Alex W. Wyatt, Joshua M. Lang, Shuang G. Zhao   +26 more
doaj   +5 more sources

Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA [PDF]

Molecular Oncology
Liquid biopsies containing circulating tumor DNA (ctDNA) are important biomarkers across several forms of cancer. The detection of mutations in cell‐free DNA (cfDNA) indicates the presence of ctDNA.
Christoffer Trier Maansson, Anders Lade Nielsen, Boe Sandahl Sorensen   +2 more
doaj   +3 more sources

DECIPHER-PRAD: an advanced fragmentomics-based cell-free DNA assay for prostate cancer early detection [PDF]

Cell Communication and Signaling
Early detection of prostate cancer is limited by the poor specificity of prostate-specific antigen (PSA)-based screening. Cell-free DNA (cfDNA) fragmentomics offers a promising non-invasive approach to improve screening accuracy and risk stratification ...
Shun Zhang, Junlong Zhuang, Shuang Chang   +2 more
exaly   +3 more sources

A multi-center study for colorectal cancer early detection in high-risk disease patients using cell-free fragmentomics assay [PDF]

Cancer Cell International
Background Early detection of colorectal cancer (CRC) is crucial for improving patient survival. This innovative multi-center study aims to develop a non-invasive blood-based assay using cell-free DNA (cfDNA) fragmentomics to differentiate CRC from ...
Bing Gu, Dongqin Zhu, Xiuxiu Xu
exaly   +3 more sources

Multidimensional roles of cfDNA fragmentomics in preeclampsia: from placental hypoxia and TLR9 inflammation to clinical risk stratification [PDF]

Frontiers in Medicine
Cell-free DNA (cfDNA) has emerged as a pivotal biomarker for predicting preeclampsia (PE), a multisystem syndrome characterized by placental hypoperfusion and systemic inflammation.
Ziyi Guo, Bin Zhang, Di Yang, Li Wang
exaly   +4 more sources

Seminal plasma cfDNA fragmentomics landscape delineates male infertility subtypes [PDF]

Clinical Epigenetics
Background While cell-free DNA (cfDNA) fragmentomics has transformed liquid biopsy applications in prenatal screening and oncology, its potential in male reproductive health remains unexplored.
Xiaoyu Wu, Fan Meng, Huiping Zhang, Zeqing Li, Kai Zhao   +4 more
doaj   +4 more sources

Longitudinal profiling of hormone receptor positive, HER2 negative metastatic breast cancer through droplet digital PCR-based circulating tumor DNA fragmentomics [PDF]

Translational Oncology
Background: In the context of hormone receptor positive, HER2 negative Metastatic breast cancer (MBC), CDK 4/6 inhibitors (CDK4/6i) combined with endocrine therapy represent the standard first-line treatment, improving Progression-Free Survival (PFS) and
Alessandro Minisini, Fabiola Giudici, Arianna Dri   +2 more
exaly   +4 more sources

Fragmentomic cfDNA Patterns in Noninvasive Prenatal Testing and Beyond

Journal of Biomedicine and Translational Research, 2021
The release of fetoplacental cell-free DNA (cfDNA) into the maternal bloodstream opened up new avenues towards noninvasive prenatal testing (NIPT) for aneuploidies, hereditary DNA mutations and other pregnancy-related developmental disorders ...
Kavish Kohabir, Rob Wolthuis, Erik A. Sistermans   +2 more
doaj   +4 more sources